{
    "clinical_study": {
        "@rank": "63798", 
        "acronym": "TERRA", 
        "arm_group": [
            {
                "arm_group_label": "TAS-102", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the effects of TAS-102 with placebo in patients with metastatic colorectal cancer\n      refractory or intolerable to standard chemotherapies."
        }, 
        "brief_title": "Study of TAS-102 in Patients With Metastatic Colorectal Cancer in Asia", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a multinational, double-blind, two-arm, parallel, randomized Phase 3 comparison\n      study evaluating the efficacy and safety of TAS-102 versus placebo in patients with\n      refractory metastatic colorectal cancer. Patients will be randomly assigned (2:1) to TAS-102\n      (experimental arm) or placebo (control arm)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Has provided written informed consent\n\n          -  Has adenocarcinoma of the colon or rectum\n\n          -  Has failed at least 2 prior regimens of standard chemotherapies for metastatic\n             colorectal cancer\n\n          -  ECOG performance status of 0 or 1\n\n          -  Is able to take medication orally\n\n          -  Has adequate organ function (bone marrow, kidney and liver)\n\n          -  Women of childbearing potential must have a negative pregnancy test and must agree to\n             adequate birth control if conception is possible. Males must agree to adequate birth\n             control."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01955837", 
            "org_study_id": "10040090"
        }, 
        "intervention": [
            {
                "arm_group_label": "TAS-102", 
                "description": "TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.", 
                "intervention_name": "TAS-102", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 9, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100142"
                    }, 
                    "name": "Peking University Cancer Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200032"
                    }, 
                    "name": "Fudan University Shanghai Cancer Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Songpa-gu", 
                        "country": "Korea, Republic of", 
                        "state": "Seoul", 
                        "zip": "138-736"
                    }, 
                    "name": "Asan Medical Center"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "phone": "+662-256-4493", 
                    "phone_ext": "14,15"
                }, 
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10330"
                    }, 
                    "name": "Chulalongkorn University & The King Chulalongkorn Memorial Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "China", 
                "Korea, Republic of", 
                "Thailand"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Double-Blind, Phase III Study of TAS-102 Versus Placebo in Asian Patients With Metastatic Colorectal Cancer Refractory or Intolerable to Standard Chemotherapies", 
        "other_outcome": {
            "measure": "Safety and tolerability evaluation will focus on adverse events and laboratory assessments.", 
            "safety_issue": "Yes", 
            "time_frame": "Until 30 day safety follow-up visit or until initiation of new anticancer treatment"
        }, 
        "overall_contact": {
            "email": "toiawaseCD1@taiho.co.jp", 
            "last_name": "Taiho Pharmaceutical Co., Ltd. Clinical Development Dept."
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall Survival", 
            "safety_issue": "No", 
            "time_frame": "Every 8 weeks. Survival status should be collected for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met, whichever is later."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01955837"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Progression-free survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "Every 8 weeks. Tumor assessments will be performed until radiologic progression develops or the start of new anticancer treatment, for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met."
        }, 
        "source": "Taiho Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Taiho Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}